Roivant Sciences Ltd.
Every calculator, already run for ROIV
Open the full toolkit →You have the numbers on ROIV. Get the argument.
A written report on which of these readings actually decide the outcome for Roivant Sciences Ltd., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
13 analysts covering ROIVAnalyst Price Target Disagreement for Roivant Sciences Ltd.
Wall Street's bull case implies +72% from the current price; the bear case implies +14%. A 58% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ROIV
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indicat…
ROIV — frequently asked
Is ROIV a buy right now?
Wall Street's consensus rating on Roivant Sciences Ltd. is Strong Buy across 13 analysts, with a mean price target of $48.91 (+36% vs. the current $36.05). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ROIV's next earnings date?
Roivant Sciences Ltd. is next scheduled to report earnings around Nov 9, 2026. A full ROIV research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Roivant Sciences Ltd.?
Analysts covering Roivant Sciences Ltd. (ROIV) range from a bear-case target of $41.00 to a bull-case high of $62.00, with a mean consensus target of $48.91 across 11 analysts. The spread of $21.00 (58% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Roivant Sciences Ltd. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Roivant Sciences Ltd.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ROIV research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Roivant Sciences Ltd., in minutes. 3 free reports included with every account — no credit card required.